ANDA 207521, held by Somerset Therapeutics. Dexamethasone Sodium Phosphate.
As of Nov 21, 2026, ANDA 207521 (Dexamethasone Sodium Phosphate), held by Somerset Therapeutics, was first approved by FDA on Jun 8, 2018, with 1 approved supplement and 0 published complete response letters.
INDICATIONS A. Intravenous or intramuscular administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 8, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexamethasone Sodium PhosphateEQ 4MG PHOSPHATE/ML · injectable;injection | Dexamethasone Sodium Phosphate | Rx |
| Jun 5, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 8, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters